...O descubre lo más buscado en Rankia
Rankia USA Rankia Argentina Rankia Argentina Rankia Chile Rankia Chile Rankia Colombia Rankia Colombia Rankia España Rankia España Rankia México Rankia México Rankia Perú Rankia Perú Rankia Portugal Rankia Portugal
Entrar
Acceder
  2. Perfil de anaramos

anaramos
TOP 100

Rankiano desde hace casi 9 años

«Después de nada, o después de todo/ supe que todo no era más que nada.»

7.557
Publicaciones
17.200
Recomendaciones
38
Seguidores
35
Posición en Rankia
45
Posición último año
Resumen
Respuestas 7538
Comentarios 19
Recomendados 24460
Guardados 1496
03/06/20 08:19
Ha respondido al tema Farmas USA
Boom de antidepresivos. Si alguien sigue alguna interesante, que griteDrug shortagesOne of the most widely prescribed antidepressant medications in the U.S. has fallen into short supply, according to a new list from the FDA. Pfizer (NYSE:PFE) said some versions of its name-brand Zoloft, such as 100 milligram tablets in 100-count bottles, were scarce because of higher demand during COVID-19, while generics faced shortages of certain ingredients. Zoloft prescriptions climbed 12% Y/Y to 4.9M in March, the most ever in the U.S., according to data compiled by Bloomberg, but receded to 4.5M in April.
Ir a respuesta
03/06/20 04:36
Ha respondido al tema Farmas USA
GTHXPensando en alto...Mucho institucional dentro. Habría que mirar si andan saliendo. PO muy altos vs. precio actual. La FDA les perdona la fase 3 y les deja presentar NDA. Tienen ciento y pico millones en cash..Se enfrentan a la fase de comercialización. Por qué coño nadie les hace una colocación y se van con los de Hércules. O son idiotas o ya están vendidos.Miraré movimientos directivos. Ya no es un corto tan cómodo, pero me recuerda tanto a SGYP...Se agradecerán divagaciones.
Ir a respuesta
03/06/20 04:02
Ha respondido al tema Farmas USA
GTHX Rintodestrant combination trial with palbociclib expected to initiate in 2Q20Pivotal trial of trilaciclib in colorectal cancer expected to begin in 4Q20. In 2Q20, the company discussed the design of a registrational clinical trial of trilaciclib in colorectal cancer with the FDA at a pre-Phase 3 meeting. The trial is on track to begin in the fourth quarter of 2020I-SPY 2 neoadjuvant breast cancer trial including trilaciclib on track for 2Q20 initiation. Trilaciclib was selected for inclusion in the ongoing Phase 2 I-SPY 2 TRIAL™ based on compelling overall survival (OS) findings in a Phase 2 triple-negative breast cancer (TNBC) trial (press release here). The I-SPY trial will generate data across a range of breast cancer subtypes that will allow the company to evaluate trilaciclib in combination with several broadly-used chemotherapy classes and an anti-PD-1 immunotherapy
Ir a respuesta
03/06/20 03:28
Ha respondido al tema Farmas USA
GTHXInvesting, he visto que has llevado de estas alguna vez. ¿Puedes contarme algo sobre futuros hitos?Les acaban de conceder un préstamo los de Hercules Capital con unas condiciones en tres tramos. La última vez que vi uno así creo que fue el de SGYP. Las condiciones estaban montadas directamente para reventar la empresa y vendérsela al mejor postor.Las investigo con la.idea de un corto tranquilo,.dilatado en meses, pero sin perder de vista el pipeline. Gracias.8K del préstamo:https://newsfilter.io/articles/8-k-form---current-report-items-101-203-and-901---g1-therapeutics-inc-0001560241-filer-e2c0ec8d4053a2205df8b980ef6cd2c4Voy editando mensaje según amplío. Por lo pronto, el momento de entrada parece tras presentar solicitud NDA este mes:G1 plans to use the proceeds to fund commercialization and further development of trilaciclib, itsfirst-in-classinvestigational therapy designed to improve outcomes for people with cancer treated with chemothera py.“We expect to file a New Drug Application for trilaciclib later this month for myelopreservation in small cell lung cancer. This financing strengthens our balance sheet as we prepare for commercial launch in our first indication and to execute a robust development plan to evaluate trilaciclib in additional tumor typeThe $100 million credit facility from Hercules is available in four tranches: the first tranche of $30 million is available at loan closing, of which the company plans to utilize $20 million immediately, with the remaining $10 million available through March 31, 2021; the second tranche of $20 million will be available upon achievement of U.S. Food and Drug Administration approval of trilaciclib in small cell lung cancer and initiation of a registrational trial in metastatic colorectal cancer, to be available from January 1, 2021 through December 15, 2021; an additional tranche of $30 million will be available from April 1, 2021 through December 31, 2022, subject to certain terms and conditions, including in connection with net product revenues for trilaciclib; and a final tranche of $20 million will be available prior to December 31, 2022 to support strategic initiatives, subject to future approvals by Hercules..
Ir a respuesta
02/06/20 17:34
Ha respondido al tema Farmas USA
ARNACantor PO 88$Shares of Arena Pharmaceuticals (NASDAQ:ARNA) are up 13% at 2:13 p.m. EDT because its rival, Bristol Myers Squibb (NYSE:BMY), reported positive data on Zeposia in patients with ulcerative colitis. Zeposia targets the sphingosine-1-phosphate (S1P) receptor, just like Arena's etrasimod.So whatTypically, good data from a rival drugmaker would send shares down, not up, but ulcerative colitis is a common enough disease -- around a million Americans have it -- that there's enough room in the marketplace for more than one drughttps://www.fool.com/investing/2020/06/02/heres-why-arena-pharmaceuticals-jumped-higher-toda.aspx
Ir a respuesta

Lo que sigue anaramos

 pepapi
Remora Bolsa
jgcoboss3
Ver todos
RankiaPro: La web para los profesionales de la gestión patrimonial
Copyright © 2003 - 2020 Rankia S.L. Aviso legal · Política de privacidad · Política de cookies · Contacta con nosotros · Quiénes somos